Top Banner
Principles of Clinical Pharmacology Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program Office of Clinical Research Training and Medical Education National Institutes of Health Clinical Center September 3, 2015 Lipsett Amphitheater
88

Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical...

Mar 10, 2018

Download

Documents

tranthien
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

Principles of Clinical Pharmacology Juan J.L. Lertora, M.D., Ph.D.

Director Clinical Pharmacology Program

Office of Clinical Research Training

and Medical Education National Institutes of Health

Clinical Center

September 3, 2015 Lipsett Amphitheater

Page 2: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

2

COURSE FOCUS

Scientific basis of drug use, development and evaluation

Not Therapeutics

Emphasis is on General Principles for both “old” and “new” drugs

Page 3: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

3

Recommended Text

Pharmacology, Third Edition by Arthur J. Atkinson, Jr., et al,

published by Academic Press

Photo of Book Cover

Page 4: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

4

PCP Course Team – OCRTME

LaTanya Bailey

Course Cordinator

301-435-9425

[email protected]

Daniel McAnally

Nicole Tate

Page 5: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

5

CLINICAL PHARMACOLOGY

Part I: Overview

General Scope of the Discipline

Historical Notes

Role of Clinical Pharmacologists

Variability in Drug Response

Adverse Drug Reactions

Drug Development

Page 6: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

6

PHARMACOLOGY

The study of drugs and biologics

and their actions in living organisms

Drugs: “small molecules”, chemicals

Biologics: “large molecules”, peptides, antibodies

Page 7: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

7

CLINICAL PHARMACOLOGY

THE STUDY OF DRUGS AND BIOLOGICS IN HUMANS

Page 8: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

8

Translational Sciences

Knowledge acquired in animal or in silico models of disease, ex-

vivo studies in human tissues, or in vivo studies in healthy or

diseased humans is translated into effective treatment for

patients.

Clinical Pharmacology is a translational discipline essential for

rational drug development and therapeutics in humans.

Page 9: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

9

FOUNDERS OF AMERICAN CLINICAL

PHARMACOLOGY

Photos of Harry Gold and Walter Modell

Page 10: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

10

Partial List of GOLD and MODELL

Accomplishments

1937 – Introduced Double-Blind Clinical Trial Design 1

1939 – Initiated Cornell Conference on Therapy

1953 – Analized Digoxin Effect Kinetics to Estimate Absolute

Bioavailability as well as Time-Course of Chronotropic

Effects2

1960 - Founded Clinical Pharmacology and Therapeutics

1 Gold H, Kwit NT, Otto H. JAMA 1937;108:2173-2179.

2 Gold H, Cattell McK, Greiner T, Hanlon LW, Kwit NT, Modell

W,

Cotlove E, Benton J, Otto HL. J Pharmacol Exp Ther

1953:109;45-57.

Page 11: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

11

HISTORY OF CLINICAL PHARMACOLOGY

Albert Sjoerdsma, M.D., Ph.D.

Experimental Therapeutics Branch

National Heart Institute (1958-1971)

Lou Gillespie, John Oates, Leon Goldberg, Richard

Crout, Ken Melmon

Serotonin, carcinoid syndrome, antidepressant drugs

Pheochromocytoma, antihypertensive drugs

Page 12: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

12

PROFESSIONAL GOALS OF

CLINICAL PHARMACOLOGISTS

Discover, develop and evaluate new medicines

Optimize the use of existing medicines, find new indications

Define the basis for variability in therapeutic and toxic responses to

medicines

Page 13: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

13

Interindividual Variation in Drug Exposure

(AUC)

Karim A et al, 2007

Chart showing variability in AUC for pioglitazone and metformin

in males and females.

J Clin Pharmacol 2007;47:37-47

Page 14: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

14

Nortriptyline Drug Exposure

Impact of CY2D6 Polymorphism

Impact of CYP2D6 Polymorphism

Chart showing the impact of CYP2D6 gene duplication

Dalen P et al. Clin Pharmacol Ther 1998;63:444-452

Page 15: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

15

Genetics and Severe Drug Toxicity

HLA-B*5701 Abacavir hypersensitivity Flucoxacillin liver injury (DILI) HLA-B*1502 Carbamazepine-induced Stevens-Johnson syndrome

Page 16: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

16

Adverse Drug Reactions

Some toxicities can be managed and may be acceptable (risk/benefit ratio) while others are by their nature and severity unacceptable. Risk/benefit is contextual (drug and disease).

Page 17: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

17

TORSADES DE POINTES

Electrocardiogram of drug-induced arrhythmia.

Page 18: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

18

TERFENADINE METABOLISM

1

Chemical structures of Terfenadine and Terfenadine Carboxylate

1From Woosley RL, et al. JAMA 1993;269:1532-6.

Page 19: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

19

THALIDOMIDE

Chemical structure of thalidomide

Page 20: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

20

Prenatal Drug Exposure:

PHOCOMELIA

Photo of an infant with phocomelia.

Page 21: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

21

CONSEQUENCES OF THALIDOMIDE CRISIS

New FDA Regulations

(KEFAUVER-HARRIS 1962 AMENDMENTS)

Institute of Medicine-National Academy of Sciences review of

Therapeutic Claims

More Research on Causes of ADRs

NIGMS created Clinical Pharmacology Centers in the USA

Page 22: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

22

Development and Evaluation of

New Drugs

Drug discovery

Pre-clinical and clinical evaluation

Subjects of Module 5 in our course

Page 23: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

23

PHASES OF PRE-MARKETING

DRUG DEVELOPMENT

Chart showing the phases of developing a drug

Page 24: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

24

Phases of Drug Development

“Learn and Confirm” Paradigm

Phase I and II: The learning phases.

Phase III: The confirmatory phase.

Phase IV: Postmarketing - learning continues with focus on

ADRs and special populations if required.

Page 25: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

25

Drug Repurposing

Finding new biological targets and new therapeutic indications

for “old” drugs.

May shorten drug development time.

Known human pharmacokinetics.

Prior human safety data.

Page 26: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

26

Drug Repurposing (C. Austin, NCATS)

chart

Page 27: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

27

Thalidomide: Repurposing

Erythema Nodosum Leprosum Astute clinical observation of benefit

Multiple Myeloma Targeted development

These are FDA-approved indications

(immunomodulatory agent) Marketing done under a special restricted distribution

program: System for Thalidomide Education and Prescribing

Safety (S.T.E.P.S.)

Page 28: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

28

Novel FDA-Approved Indications for “Repurposed Drugs”

• Apomorphine - Parkinson’s Disease

• Sildenafil - Pulmonary Hypertension

• Taxotere - Prostate Cancer • Lamotrigine - Bipolar Disorder • Bevacizumab - Lung Cancer (non-SQ, non-SCLC) • Hydroxyurea - Sickle Cell Disease

• Minoxidil - Scalp hair re-growth (vertex in men)

Source: Product label (package insert)

Page 29: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

29

Clinical Pharmacology

Part II: Pharmacokinetics

Basic Concepts

Clinical Applications

Apparent Volume of Distribution

Clearance

First-order Kinetics

Michaelis-Menten Kinetics

Page 30: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

30

PHARMACOKINETICS

The QUANTITATIVE ANALYSIS of the TIME COURSE of

DRUG

ABSORPTION,

DISTRIBUTION,

METABOLISM, and

EXCRETION

Page 31: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

31

Pharmacokinetics – Pharmacodynamics

Chart

Page 32: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

32

Use of Pharmacokinetics

• Basis for rational dose selection in therapeutics

• Development and evaluation of new drugs

• Basic studies of drug distribution (PET Scan)

Page 33: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

33

Dose – Response Relationship

A central tenet of pharmacology

The careful study of “drug exposure – response” relationships is central

to finding “the right dose” for a given therapeutic indication

“Exposure – response” applies to both drug efficacy and toxicity

PK/PD modeling approaches

Page 34: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

34

“Target concentration” strategy

Based on observed individual variation in drug exposure (AUC)

when using “standard” doses.

Attempts to “individualize” therapy when therapeutic and toxic

ranges of drug concentrations in plasma have been established.

Optimize efficacy, minimize toxicity.

Page 35: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

35

TARGET CONCENTRATION STRATEGY

ESTIMATE INITIAL DOSE

TARGET LEVEL

LOADING DOSE

MAINTENANCE DOSE

BEGIN THERAPY

ASSESS THERAPY

PATIENT RESPONSE

DRUG LEVEL

REFINE DOSE ESTIMATE

ADJUST DOSE

Page 36: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

36

DRUG CANDIDATES FOR TDM

• Low therapeutic index • No physiologic endpoints or

biomarkers to guide dosage • Pharmacokinetics vary widely between

individuals • Need to monitor adherence?

Page 37: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

37

FIRST DESCRIPTION OF THERAPEUTIC DRUG

MONITORING

Article

Wuth O. JAMA 1927;88:2013-17

Page 38: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

38

First Academic Clinical Drug Analysis Lab

Arthur J. Atkinson, Jr., M.D.

Northwestern Memorial Hospital Chicago, Illinois

Page 39: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

39

TARGET CONCENTRATION

STRATEGY

ESTIMATE INITIAL DOSE

TARGET LEVEL

LOADING DOSE

MAINTENANCE DOSE

Page 40: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

40

DIGOXIN Levels in TOXIC and

NONTOXIC Patients*

graph

* From Smith TW and Haber E. J Clin Invest

1970;49:2377-86

Page 41: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

41

TRADITIONAL Guidelines

for DIGOXIN Levels

THERAPEUTIC RANGE: 0.8 - 1.6 ng/mL

POSSIBLY TOXIC LEVELS: 1.6 - 3.0

ng/mL

PROBABLY TOXIC LEVELS: > 3.0

ng/mL

Page 42: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

42

SURVIVAL as a function of DIGOXIN LEVEL

measured after 1 Month Rx*

* Rathore SS, et al. JAMA 2003;289:871-8

Page 43: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

43

PROPOSED Range of DIGOXIN LEVELS for

OPTIMAL THERAPY in CHF

New Therapeutic Range: 0.5 - 0.9 ng/mL

Benefit results from INHIBITION OF

SYMPATHETIC NERVOUS SYSTEM rather

than ↑ INOTROPY

Question: Doses of digoxin used in this study

should have resulted in higher levels? Study

limitation: No digoxin levels done after one month

in study (patients seen for 48 months).

Page 44: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

44

TARGET CONCENTRATION STRATEGY

ESTIMATE INITIAL DOSE

TARGET LEVEL

LOADING DOSE

MAINTENANCE DOSE

BASED ON CONCEPT OF DISTRIBUTION

VOLUME

Page 45: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

45

DIGOXIN LEVELS after IV Dose

graph

Page 46: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

46

SINGLE COMPARTMENT MODEL

equation

Page 47: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

47

3 DISTRIBUTION VOLUMES

equations

Page 48: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

48

INITIAL DIGITALIZATION

picture

Page 49: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

49

DISTRIBUTION DELAYS ONSET

of DIGOXIN Chronotropic Action*

Graph

* From Gold H, et al. J Pharmacol Exp Ther

1953;109:45-57.

Page 50: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

50

TARGET CONCENTRATION STRATEGY

ESTIMATE INITIAL DOSE

TARGET LEVEL

LOADING DOSE

MAINTENANCE DOSE

BASED ON CONCEPTS OF ELIMINATION

HALF LIFE

AND CLEARANCE

Page 51: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

51

ELIMINATION HALF-LIFE

ELIMINATION HALF-LIFE IS THE TIME

REQUIRED FOR THE PLASMA

CONCENTRATION (OR TOTAL BODY

STORES) OF A DRUG TO FALL TO HALF OF

THE CONCENTRATION (OR AMOUNT)

PRESENT AT SOME PREVIOUS TIME.

Page 52: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

52

ELIMINATION PARAMETERS

equation

t1/2 = elimination half life

k = elimination rate constant

CLE = elimination clearance

Page 53: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

53

MAINTENANCE DIGOXIN THERAPY

Image

Page 54: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

54

DIGOXIN CUMULATION

.25 x 2/3 = .17 DOSE #1

+.25 DOSE #2

.42 x 2/3 = .28

+.25 DOSE #3

.53 x 2/3 = .36

+.25 DOSE #4

.61 x 2/3 = .41

+.25 DOSE #5

.66 x 2/3 = .44

+.25 DOSE #6

.69 x 2/3 = .46

+.25 DOSE #7

.71

Page 55: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

55

CUMULATION FACTOR

equation

τ = dose interval

k = elimination rate constant

Page 56: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

56

ELIMINATION RATE CONSTANT

equation

Page 57: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

57

LOADING & MAINTENANCE DOSES

Graph

Page 58: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

58

TIME-COURSE OF DIGOXIN CUMULATION

graph

Page 59: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

59

Introduction to Clearance

Clearance is a “primary” parameter in the pharmacokinetic analysis of drug distribution and elimination. Understanding the concept of clearance is essential for drug evaluation and use in clinical medicine.

Page 60: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

60

CREATININE CLEARANCE EQUATION

U = URINE CONCENTRATION

V = URINE VOLUME / TIME

P = PLASMA CONCENTRATION

Page 61: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

61

CREATININE CLEARANCE REVISITED

equations

Page 62: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

62

STEADY STATE CONCENTRATION

Continuous Creatinine Synthesis equation

Continuous Drug Infusion equation

Page 63: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

63

COCKCROFT & GAULT EQUATION*

Equation

* Cockroft DW, Gault MH: Nephron 1976;16:31-41.

Page 64: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

64

COCKCROFT & GAULT EQUATION

Equation

Page 65: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

65

RENAL FUNCTION IN PATIENTS

TOXIC FROM DIGOXIN*

Shows a chart illustrating that impaired renal function increases

risk of digoxin toxicity.

* From Piergies AA, et al. Clin Pharmacol Ther 1994;55:353-8.

Page 66: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

66

MDRD Study Equation

Modification of Diet in Renal Disease (MDRD)

This equation (many versions) provides an estimate of

glomerular filtration rate (eGFR)

To be discussed in lecture on PK alterations in renal disease

Page 67: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

67

CKD-EPI Collaboration Equation

Chronic Kidney Disease (CKD)

Epidemiology Collaboration Equation

More accurate than MDRD equation in

estimating GFR (eGFR)

Less bias if GFR >60 ml/min/1.73 m2

To be discussed in lecture on PK

alterations in renal disease

Page 68: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

68

STEADY STATE CONCENTRATION Continuous infusion: equation

Intermittent dosing: equation

Page 69: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

69

STEADY STATE CONCENTRATION

NOT DETERMINED BY LOADING DOSE

MEAN STEADY STATE

CONCENTRATION

NOT DETERMINED BY Vd

PEAK AND TROUGH ARE AFFECTED BY

Vd

Page 70: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

70

Vd AFFECTS PEAK AND TROUGH

BUT NOT MEAN LEVELS

Graph

Page 71: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

71

STEADY STATE CONCENTRATION

NOT DETERMINED BY LOADING DOSE

MEAN STEADY STATE

CONCENTRATION NOT DETERMINED

BY Vd

CHANGES IN MAINTENANCE DOSE

RESULT IN DIRECTLY PROPORTIONAL

CHANGES IN CSS FOR MOST DRUGS

Page 72: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

72

FOR MOST DRUGS, Css IS

PROPORTIONAL TO DOSE (Dosing Rate)

CONTINUOUS INFUSION:

Equation

INTERMITTENT DOSING:

Equation

Page 73: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

73

SOME DRUGS NOT ELIMINATED

BY FIRST ORDER KINETICS

PHENYTOIN (DILANTIN)

ETHYL ALCOHOL

ACETYLSALICYLIC ACID (ASPIRIN)

Page 74: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

74

PHENYTOIN HYDROXYLATION

Image

Page 75: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

75

Graph

Page 76: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

76

PHENYTOIN KINETICS

in Normal Subjects

Graph

Page 77: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

77

STEADY STATE EQUATION

SS

SSm

max

SSE

CCK

V/τDOSE

KINETICS MENTEN-MICHAELIS

CCL/τDOSE

KINETICS ORDER FIRST

Page 78: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

78

RELATIONSHIP OF PLASMA LEVEL TO

PHENYTOIN DOSE*

PHENYTOIN DOSE PLASMA LEVEL

(mg/day) µg/mL

300 10

400 20

500 30

(THERAPEUTIC RANGE: 10 – 20 μg/mL)

* From: Kutt H, McDowell F: J Am Med Assoc

1968;203:969-72.

Page 79: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

79

PATIENT WHO BECAME TOXIC ON A PHENYTOIN DOSE OF 300 mg/day

graph

Page 80: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

80

BASIS OF APPARENT FIRST-ORDER KINETICS

Equations

Page 81: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

81

PHARMACOKINETICS

• PRACTICE PROBLEMS AT END OF CHAPTER

2

WITH ANSWERS IN APPENDIX II

• EQUATIONS DERIVED IN “PRINCIPLES OF

CLINICAL PHARMACOLOGY” TEXTBOOK

Page 82: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

82

Historical Overview

The establishment of experimental pharmacology as a discipline in Europe and the USA in the 19

th and 20

th

centuries.

Page 83: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

83

John Jacob Abel

“Father of American Pharmacology” First fulll-time Professor in Materia Medica and Therapeutics at the University of Michigan (1891) Founder , “Journal of Pharmacology and Experimental Therapeutics” (1896)

Page 84: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

84

John Jacob Abel Crystallization of insulin

Research on tetanus toxin

Study of the phthaleins

Invention of the artificial kidney

(vividialysis or vividiffusion)

Page 85: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

85

Oswald Schmiedeberg

Professor of Pharmacology at Strassbourg (1872)

Pioneer studies on autonomic nervous system, nicotine,

muscarine

Chloroform blood levels

Page 86: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

86

Rudolph Bucheim

Professor at the University of Dorpat (now Tartu, Estonia)

(1847-1867).

Established the first experimental pharmacology laboratory in

search for proof of drug actions.

Page 87: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

87

LINEAGE of Modern

CLINICAL PHARMACOLOGY

Pater Familias

Rudolph Bucheim

Founding Fathers

US Europe

Harry Gold Paul Marini

Page 88: Principles of Clinical Pharmacology - pcp. · PDF fileintroduction to clearance ... • practice problems at end of chapter ... • equations derived in “principles of clinical pharmacology”

88

LINEAGE OF Modern

Clinical Pharmacology

Chart showing lineage of modern clinical pharmacology with Pater

Familias and Rudolph Bucheim at the top level followed by the

Founding Fathers in the United States, Harry Gold and Walter

Modell along side the Founding Father in Europe Paul Martini.

Below those names are the names of the Renaissance Leaders in

the United States Ken Melmon, John Oates, Leon Goldberg, Dan

Azarnoff, Jan Koch-Weser and Lou Lasagna next to the

renaissance leaders in Europe Folke Sjoqvist and Collin Dollery.